Magnetic Resonance Imaging (MRI) Biomarker Study: an observational study to assess differential changes that occur in the brains of participants with various neurodegenerative diseases using MRI technology.
- Conditions
- Alzheimer's disease [AD]Frontotemporal dementia [FTD]Parkinson's disease [PD]motor neuron disease [ALS]progressive supranuclear palsy [PSP]corticobasal degeneration [CBD]Dementia with Lewy BodiesNeurological - Neurodegenerative diseasesNeurological - Alzheimer's diseaseNeurological - Parkinson's disease
- Registration Number
- ACTRN12618002032235
- Lead Sponsor
- niversity of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
oVisual and auditory acuity, adequate for neuropsychological testing
oEnglish language proficiency, adequate for comprehensive neuropsychological testing
oWilling to undergo repeated MRIs (3T and 7T MRIs)
oHealthy control: without any history of neurological or major psychiatric illness; and who are free of any cognitive symptoms (e.g. Mini Mental State Exam (MMSE) score greater than or equal to 26/30, Addenbrooke’s Cognitive Examination (ACE) score greater than or equal to 88/100, Clinical Dementia Rating (CDR) equal to 0 ) ; and whose general health is good enough to lie comfortably in an MRI scanner (e.g. does not have severe arthritis or breathlessness etc.)
oPatients group will be divided into 7 different subgroups based on their clinical diagnosis.*
oPatient Group 1: Alzheimer’s disease (AD), including prodromal states such as mild cognitive impairment
oPatient Group 2: Parkinson’s disease (PD) patients
oPatient Group 3: Dementia with Lewy Bodies (DLB)
oPatient Group 4: Frontotemporal dementia (FTD)
oPatient Group 5: Progressive supranuclear palsy (PSP)
oPatient Group 6: Corticobasal degeneration (CBD), including patients with undifferentiated akinetic/rigid syndromes, i.e. where the assessing neurologist is confident of a degenerative disease but where the clinical features preclude a more precise diagnosis such as PD, PSP, CBD
oPatient Group 7: Amyotrophic lateral sclerosis (ALS)
o* Diagnosis will be based on patient and carer interview & questionnaire, physical examination, brain scans, cognitive tests (MMSE, ACE, CDR) and/or motor function tests (ALS functional rating scale revised (ALSFRS-R), Unified Parkinson’s disease rating scale (UPDRS), Hoen and Yahr).
oPregnancy#
oKnown history of claustrophobia#
oContra-indication to MRI#: cardiac pacemakers, aneurysm clips, metal implants, hearing aid/implant, electrical neurostimulators, joint replacement etc. in accordance with the standard operating procedures of the Centre for Advanced Imaging, UQ. #NOTE: Participants will be re-interviewed by a radiographer on the day of imaging at the Centre for Advanced Imaging, UQ.
oHistory of other neurological diseases (including clinical stroke, multiple sclerosis, tumour, epilepsy, or any other disease) that could confound interpretation of the MRI scan data
oHistory of major psychiatric illness (psychosis, major depression)
oAny medical condition that could make scanning hazardous/uncomfortable (e.g. difficulty lying flat due to cardiac, respiratory or rheumatological disease)
oFor the patient group only
oUnavailability of a close relative/companion who can assist the patient to attend the research facility.
oAdvanced cognitive impairment rendering the patient untestable on neuropsychological tests or unable to follow the instructions for MRI scanning.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exploratory Outcome <br>Disease specific pathological patterns in the potential areas of interest (Putamen, substantia nigra, dentate, motor cortex, red nucleus, and pallidum) using QSM and DTI techniques. <br><br>[Single time point ]
- Secondary Outcome Measures
Name Time Method Exploratory Outcome <br>Results from 7 Tesla MRI will provide more detailed information of brain tissue changes. <br><br>We expect to reveal further disease specific pathological patterns by measuring (i) changes brain tissue iron deposition in defined brain areas, (ii) volume changes of hippocampal sub-fields, and (iii) changes of tissue micro structure in the corpus callosum, [Single time point]